A 1-year open-label safety study of CVT-301 for OFF episodes in Parkinson’s disease

Takeaway

  • There were no clinically significant differences in pulmonary function in those treated with inhaled CVT-301 for up to 1-year of treatment for OFF episodes in Parkinson’s disease (PD) compared with standard of care (SOC) oral levodopa.

Why this matters

    The open-label study supports previous clinical trials of the safety and effectiveness of CVT-301, indicating CVT-301 does not pose a significant pulmonary safety concern for up to 1-year of treatment in those with PD.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.